Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
White Paper
September 05, 2017

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

Current MRD detection landscape, key considerations for each approach, and current advancements that will contribute to further improvements in MRD detection

Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma. 

Two approaches of specific interest due to the innovation they brought in MRD assessment are multi-color flow cytometry (MFC) and genomic approaches such as next-generation sequencing (NGS). Each technique has advantages and disadvantages, and the most appropriate method may be chosen based on tumor load, type of malignancy, presence or absence of disease-specific markers, the technological limit of detection, turn-around time (TAT) requirement, cost and other factors.

This paper explores, in further detail, the current landscape of MRD detection, key considerations for each approach, and current advancements that will contribute to even further improved MRD detection in the future.

Authors:
Franklin Sedarat, M.D. MSc, Director of Hematopathology
Mark Edinger, Scientific Advisor, Flow Cytometry
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics


Related Services:
Minimal Residual Disease: Finding the Right Test for the New Definition of Remission

Measurement of Residual Disease for improved oncology trial outcomes

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

What you should know for your clinical development program

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More